Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03042793 | Vaccination With PD-L1 Peptide Against Multiple Myeloma | completed | Phase 1 | 10 | Lene Meldgaard KnudsenOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT00985907 | Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma(DMV) | terminated | Phase 1 / Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04275583 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04120350 | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty(REMLA) | unknown | Phase 1 / Phase 2 | 47 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT00903968 | Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03492138 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | Ajai ChariOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT00729118 | Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT01916135 | PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative | completed | Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2020 | clinicaltrials |
| NCT01212952 | Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 50 | Mayo ClinicOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT00860171 | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT03266692 | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 15 | Cogent Biosciences, Inc.INDUSTRY | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02492750 | Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | completed | Phase 1 | 14 | Mayo ClinicOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma | terminated | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 16, 2020 | clinicaltrials |
| NCT02756728 | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 5 | BioInvent International ABINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02951728 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma(DR-CHOP) | unknown | Phase 1 / Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03483688 | A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects | completed | Phase 1 | 6 | Peking Union Medical College HospitalOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00854139 | Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD) | completed | Phase 1 | 10 | Massachusetts General HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT04295018 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02784483 | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma | terminated | Phase 1 | 2 | Yale UniversityOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT03106428 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | completed | Phase 1 | 67 | MedImmune LLCINDUSTRY | 3 | Feb 28, 2020 | clinicaltrials |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 7 | BayerINDUSTRY | 3 | Feb 26, 2020 | clinicaltrials |
| NCT00918723 | Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02603445 | Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 24, 2020 | clinicaltrials |
| NCT03051841 | CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03150316 | CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01691898 | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(ROMULUS) | completed | Phase 1 / Phase 2 | 231 | Genentech, Inc.INDUSTRY | 6 | Feb 21, 2020 | clinicaltrials |
| NCT01049945 | Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 70 | Mayo ClinicOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03068351 | Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma | completed | Phase 1 | 24 | Hoffmann-La RocheINDUSTRY | 3 | Feb 7, 2020 | clinicaltrials |
| NCT00003954 | Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 2 | Feb 6, 2020 | clinicaltrials |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 31, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP(SMR-3184) | terminated | Phase 1 / Phase 2 | 1 | Allarity TherapeuticsINDUSTRY | 1 | Jan 30, 2020 | clinicaltrials |
| NCT00005803 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 / Phase 2 | 76 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT03579927 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT00558675 | A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy | completed | Phase 1 / Phase 2 | 6 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01464112 | A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 18 | Janssen Research & Development, LLCINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03015922 | Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma(MUKeleven) | unknown | Phase 1 | 4 | University of LeedsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00048412 | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | completed | Phase 1 / Phase 2 | 40 | Baylor College of MedicineOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT02340936 | Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma | completed | Phase 1 / Phase 2 | 53 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT00481871 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | completed | Phase 1 / Phase 2 | 119 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01851551 | Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL | completed | Phase 1 / Phase 2 | 22 | Acrotech Biopharma Inc.INDUSTRY | 2 | Jan 3, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jul 7, 2020source: clinicaltrials